Topoisomerase induced DNA damage coupled diseases and therapeutic potential

Topoisomerase induced DNA damage coupled diseases and therapeutic potential

Автор: Dutta Madhurima, Mandal Somnath

Журнал: Журнал стресс-физиологии и биохимии @jspb

Статья в выпуске: 3 т.20, 2024 года.

Бесплатный доступ

Topoisomerase is an essential enzyme which regulates the topological state of DNA supercoils during replication and transcription. Topoisomerases cleave either one or two DNA strands and then re-join the cleaved strands after passing the intact strand or a double strand through the gap respectively. During relaxation of supercoiled DNA, if topoisomerase is trapped by drugs or alteration of DNA structure, they stabilize topoisomerase-DNA cleavage complex which leads to DNA damage. If Topoisomerase cleavage complex is trapped by any anticancer or others drug, exogenous and endogenous DNA lesion involving mismatches, abasic sites, oxidative damage etc. it may cause DNA damage. DNA damages leads to several diseases such as tumorigenesis, autoimmune disease, Angelman syndrome, SCAN1, SCAR23, Papillary Thyroid Cancer (PTC), cancer therapy-related acute myeloid leukemia. Topoisomerase uses as a potential drug target to manage infectious diseases like leishmaniasis, Chagas disease, pneumococcal, dengue, yellow fever, corona virus, gastrointestinal infection. Here we review the recent information about the topoisomerase mediated DNA damage, related diseases, role of topoisomerase in heterochromatin structure and uses of topoisomerase as drug target in many diseases.

Еще

Camptothecin, etoposide, doxorubicin, xenotoxic, non-hodgkin’s lymphoma

Короткий адрес: https://sciup.org/143182799

IDR: 143182799

Список литературы Topoisomerase induced DNA damage coupled diseases and therapeutic potential

  • Aguilera, A., & Garcia-Muse, T. (2012). R loops: from transcription byproducts to threats to genome stability. Molecular cell, 46(2), 115-124.
  • Alt, F. W., & Schwer, B. (2018). DNA double-strand breaks as drivers of neural genomic change, function, and disease. DNA repair, 71, 158-163.
  • Antony, S., Jayaraman, M., Laco, G., Kohlhagen, G., Kohn, K. W., Cushman, M., & Pommier, Y. (2003). Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-111-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I. Cancer Research, 63(21), 7428-7435.
  • Austin, C. A., & Marsh, K. L. (1998). Eukaryotic DNA topoisomerase lip. Bioessays, 20(3), 215-226.
  • Baranello, L., Bertozzi, D., Fogli, M. V., Pommier, Y., & Capranico, G. (2010). DNA topoisomerase I inhibition by camptothecin induces escape of RNA polymerase II from promoter-proximal pause site, antisense transcription and histone acetylation at the human HIF-1a gene locus. Nucleic acids research, 38(1), 159-171.
  • Barrows, N. J., Anglero-Rodriguez, Y., Kim, B., Jamison, S. F., Le Sommer, C., McGee, C. E.....& Garcia-Blanco, M. A. (2019). Dual roles for the ER membrane protein complex in flavivirus infection: viral entry and protein biogenesis. Scientific reports, 9(1), 9711.
  • Barthelmes, H. U., Grue, P., Feineis, S., Straub, T., & Boege, F. (2000). Active DNA topoisomerase IIa is a component of the salt-stable centrosome core. Journal of Biological Chemistry, 275(49), 38823-38830.
  • Bauman, M. E., Holden, J. A., Brown, K. A., Harker, W. G., & Perkins, S. L. (1997). Differential immunohistochemical staining for DNA topoisomerase II alpha and beta in human tissues and for DNA topoisomerase II beta in non-Hodgkin's lymphomas. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc, 10(3), 168-175.
  • Beadle, G., Baade, P., & Fritschi, L. (2009). Acute myeloid leukemia after breast cancer: a population-based comparison with hematological malignancies and other cancers. Annals of oncology, 20(1), 103-109.
  • Bendixen, C., Thomsen, B., Alsner, J., & Westergaard, O. (1990). Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription. Biochemistry, 29(23), 5613-5619.
  • Berger, J. M., Fass, D., Wang, J. C., & Harrison, S. C. (1998). Structural similarities between topoisomerases that cleave one or both DNA strands. Proceedings of the National Academy of Sciences, 95(14), 7876-7881.
  • Berger, J. M., Gamblin, S. J., Harrison, S. C., & Wang, J. C. (1996). Structure and mechanism of DNA topoisomerase II. Nature, 379(6562), 225-232.
  • Blattes, R., Monod, C., Susbielle, G., Cuvier, O., Wu, J. H., Hsieh, T. S.....& Käs, E. (2006). Displacement of D1, HP1 and topoisomerase II from satellite heterochromatin by a specific polyamide. The EMBO journal, 25(11), 2397-2408.
  • Boffetta, P., & Kaldor, J. M. (1994). Secondary malignancies following cancer chemotherapy. Acta Oncologica, 33(6), 591-598.
  • Broeker, P. L., Super, H. G., Thirman, M. J., Pomykala, H., Yonebayashi, Y., Tanabe, S.....& Rowley, J. D. (1996). Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood, 87(5), 1912-1922.
  • Burgin Jr, A. B., Huizenga, B. N., & Nash, H. A. (1995). A novel suicide substrate for DNA topoisomerases and site-specific recombinases. Nucleic acids research, 23(15), 2973-2979.
  • Burrow, A. A., Williams, L. E., Pierce, L. C., & Wang, Y. H. (2009). Over half of breakpoints in gene pairs involved in cancer-specific recurrent translocations are mapped to human chromosomal fragile sites. BMC genomics, 10, 1-11.
  • Capranico, G., De Isabella, P., Tinelli, S., Bigioni, M., & Zunino, F. (1993). Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II. Biochemistry, 32(12), 3038-3046.
  • Capranico, G., Kohn, K. W., & Pommier, Y. (1990). Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic acids research, 18(22), 66116619.
  • Capranico, G., Zunino, F., Kohn, K. W., & Pommier, Y. (1990a). Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry, 29(2), 562-569.
  • Champoux, J. J. (2001). DNA topoisomerases: structure, function, and mechanism. Annual review of biochemistry, 70(1), 369-413.
  • Chen, A. Y., Jemal, A., & Ward, E. M. (2009). Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer: Interdisciplinary International Journal of the American Cancer Society, 115(16), 3801-3807.
  • Chen, G. L. Yang, L., Rowe, T. C., Halligan, B. D., Tewey, K. M., Liu L. F., (1984). Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem, 259, 13560-13566.
  • Chen, H., & Eastmond, D. A. (1995). Topoisomerase inhibition by phenolic metabolites: a potential mechanism for benzene's clastogenic effects. Carcinogenesis, 16(10), 2301-2307.
  • Cheng, B., Annamalai, T., Sorokin, E., Abrenica, M., Aedo, S., & Tse-Dinh, Y. C. (2009). Asp-to-Asn substitution at the first position of the DxD TOPRIM motif of recombinant bacterial topoisomerase I is extremely lethal to E. coli. Journal of molecular biology, 385(2), 558-567.
  • Clapier, C.R., and B.R Cairns. 2009. "The biology of chromatin remodeling complexes." Annu. Rev. Biochem. 78: 273-304.
  • Covey, J. M., Jaxel, C., Kohn, K. W., & Pommier, Y. (1989). Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer research, 49(18), 50165022.
  • Dalla Rosa, I., Shar-yin, N. H., Agama, K., Khiati, S., Zhang, H., & Pommier, Y. (2014). Mapping topoisomerase sites in mitochondrial DNA with a poisonous mitochondrial topoisomerase I (Top1mt). Journal of Biological Chemistry, 289(26), 18595-18602.
  • Dalla Rosa, I., Zhang, H., Khiati, S., Wu, X., & Pommier, Y. (2017). Transcription profiling suggests that mitochondrial topoisomerase IB acts as a topological barrier and regulator of mitochondrial DNA transcription. Journal of Biological Chemistry, 292(49), 20162-20172.
  • Das, B. B., Sen, N., Ganguly, A., & Majumder, H. K. (2004). Reconstitution and functional characterization of the unusual bi-subunit type I DNA topoisomerase from Leishmania donovani. FEBS letters, 565(1-3), 81-88.
  • Davies, L., & Welch, H. G. (2006). Increasing incidence of thyroid cancer in the United States, 19732002. Jama, 295(18), 2164-2167.
  • De Vathaire, F., Hawkins, M., Campbell, S., Oberlin, O., Raquin, M. A., Schlienger, J. Y.....& Lemerle, J. (1999). Second malignant neoplasms after a first cancer in childhood: temporal pattern of risk according to type of treatment. British journal of cancer, 79(11), 1884-1893.
  • Dillon, L. W., Lehman, C. E., & Wang, Y. H. (2012). The role of fragile sites in sporadic papillary thyroid carcinoma. Journal of Thyroid Research, 2012.
  • Dillon, L. W., Pierce, L. C., Lehman, C. E., Nikiforov, Y. E., & Wang, Y. H. (2013). DNA topoisomerases participate in fragility of the oncogene RET. PloS one, 8(9), e75741.
  • Dinh, T. T., Gao, L., Liu, X., Li, D., Li, S., Zhao, Y.....& Chen, X. (2015). Correction: DNA Topoisomerase 1a Promotes Transcriptional Silencing of Transposable Elements through DNA Methylation and Histone Lysine 9 Dimethylation in Arabidopsis. Plos Genetics, 11(9), e1005452.
  • Eastmond, D. A., Mondrala, S. T., & Hasegawa, L. (2005). Topoisomerase II inhibition by myeloperoxidase-activated hydroquinone: a potential mechanism underlying the genotoxic and carcinogenic effects of benzene. Chemico-biological interactions, 153, 207-216.
  • El-Khamisy, S. F., & Caldecott, K. W. (2007). DNA single-strand break repair and spinocerebellar ataxia with axonal neuropathy-1. Neuroscience, 145(4), 1260-1266.
  • El-Khamisy, S. F., Saifi, G. M., Weinfeld, M., Johansson, F., Helleday, T., Lupski, J. R., & Caldecott, K. W. (2005). Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature, 434(7029), 108-113.
  • Enewold, L., Zhu, K., Ron, E., Marrogi, A. J., Stojadinovic, A., Peoples, G. E., & Devesa, S. S. (2009). Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiology Biomarkers & Prevention, 18(3), 784-791.
  • Feinberg, A. P., Koldobskiy, M. A., & Gondor, A. (2016). Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nature Reviews Genetics, 17(5), 284-299.
  • Felix, C. A. (1998). Secondary leukemias induced by topoisomerase-targeted drugs. Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression, 1400(1-3), 233-255.
  • Fenton, C. L., Lukes, Y., Nicholson, D., Dinauer, C. A., Francis, G. L., & Tuttle, R. M. (2000). The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. The Journal of Clinical Endocrinology & Metabolism, 85(3), 1170-1175.
  • Finn, S. P., Smyth, P., O'Leary, J., Sweeney, E. C., & Sheils, O. (2003). Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism, 88(2), 938-941.
  • Forterre, P., & Gadelle, D. (2009). Phylogenomics of DNA topoisomerases: their origin and putative roles in the emergence of modern organisms. Nucleic Acids Research, 37(3), 679692.
  • Fortune, J. M., & Osheroff, N. (2000). Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Progress in Nucleic Acid Research and Molecular Biology, 64, 2221-253
  • Frantz, C. E., Chen, H., & Eastmond, D. A. (1996). Inhibition of human topoisomerase II in vitro by bioactive benzene metabolites. Environmental health perspectives, 104(suppl 6), 1319-1323.
  • Froelich-Ammon, S. J., Gale, K. C., & Osheroff, N. (1994). Site-specific cleavage of a DNA hairpin by topoisomerase II. DNA secondary structure as a determinant of enzyme recognition/cleavage. Journal of Biological Chemistry, 269(10), 7719-7725.
  • Gilmour, D. S., Pflugfelder, G., Wang, J. C., & Lis, J. T. (1986). Topoisomerase I interacts with transcribed regions in Drosophila cells. Cell, 44(3), 401-407.
  • Gómez-Herreros, F., Romero-Granados, R., Zeng, Z., Alvarez-Quilon, A., Quintero, C., Ju, L..... & Cortés-Ledesma, F. (2013). TDP2-dependent non-homologous end-joining protects against topoisomerase II-induced DNA breaks and genome instability in cells and in vivo. PLoS genetics, 9(3), e1003226.
  • Gómez-Herreros, F., Schuurs-Hoeijmakers, J. H., McCormack, M., Greally, M. T., Rulten, S., Romero-Granados, R..... & Caldecott, K. W. (2014). TDP2 protects transcription from abortive topoisomerase activity and is required for normal neural function. Nature genetics, 46(5), 516-521.
  • Gothe, H. J., Bouwman, B. A. M., Gusmao, E. G., Piccinno, R., Petrosino, G., Sayols, S..... & Roukos, V. (2019). Spatial chromosome folding and active transcription drive DNA fragility and formation of oncogenic MLL translocations. Molecular cell, 75(2), 267-283.
  • Goto, M., Miller, R. W., Ishikawa, Y., & Sugano, H. (1996). Excess of rare cancers in Werner syndrome (adult progeria). Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 5(4), 239-246.
  • Gow, K. W., Lensing, S., Hill, D. A., Krasin, M. J., McCarville, M. B., Rai, S. N.....& Hudson, M. M. (2003). Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: an institutional experience and review of the literature. Journal of pediatric surgery, 38(11), 1574-1580.
  • Grue P, Grasser A, Sehested M, Jensen PB, Uhse A, et al. (1998). Essential mitotic functions of DNA topoisomerase IIa are not adopted by topoisomerase IIb in human H69 cells. J Biol Chem, 273, 33660-33666.
  • Harmon, F. G., Brockman, J. P., & Kowalczykowski, S. C. (2003). RecQ helicase stimulates both DNA catenation and changes in DNA topology by topoisomerase III. Journal of Biological Chemistry, 278(43), 42668-42678.
  • Harvey, G. R., Rands, A. L., & McHugh, N. J. (1996). Anti-RNA polymerase antibodies in systemic sclerosis (SSc): association with anti-topoisomerase I antibodies and identification of autoreactive subunits of RNA polymerase II. Clinical & Experimental Immunology, 105(3), 468-474.
  • He, X., van Waardenburg, R. C. A. M., Babaoglu, K., Price, A. C., Nitiss, K. C.,He, X., van Waardenburg, R. C. A. M., Babaoglu, K., Price, A. C., Nitiss, K. C.,. (2007). Mutation of a conserved active site residue converts Tyrosyl-DNA phosphodiesterase I into a DNA topoisomerase I-dependent poison. Mol. Biol. 372, 1070-1081.
  • Holm, C., Covey, J. M., Kerrigan, D., & Pommier, Y. (1989). Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer research, 49(22), 6365-6368.
  • Hsiang, Y. H., Lihou, M. G., & Liu, L. F. (1989). Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer research, 49(18), 5077-5082.
  • Hu, P. Q., Fertig, N., Medsger, T. A., & Wright, T. M. (2004). Molecular recognition patterns of serum anti-DNA topoisomerase I antibody in systemic sclerosis. The Journal of Immunology, 173(4), 2834-2841.
  • Interthal, H., Chen, H. J., & Champoux, J. J. (2005). Human Tdp1 cleaves a broad spectrum of substrates, including phosphoamide linkages. Journal of Biological Chemistry, 280(43), 36518-36528.
  • Interthal, H., Pouliot, J. J., & Champoux, J. J. (2001). The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily. Proceedings of the National Academy of Sciences, 98(21), 12009-12014.
  • Isaacs, R. J., Davies, S. L., Sandri, M. I., Redwood, C., Wells, N. J., & Hickson, I. D. (1998). Physiological regulation of eukaryotic topoisomerase II. Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression, 1400(1-3), 121-137.
  • Janssen, A., Colmenares, S. U., & Karpen, G. H. (2018). Heterochromatin: guardian of the genome. Annual review of cell and developmental biology, 34, 265288.
  • Jaxel, C., Capranico, G., Kerrigan, D., Kohn, K. W., & Pommier, Y. (1991). Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. Journal of Biological Chemistry, 266(30), 20418-20423.
  • Jimenez, M., Leon, P., Castro, L., Azcona, C., & Sierrasesumaga, L. (1995). Second tumors in pediatric oncologic patients. Report of 5 cases. Revista de medicina de la Universidad de Navarra, 40(2), 72-77.
  • Jonstrup, A. T., Thomsen, T., Wang, Y., Knudsen, B. R., Koch, J., & Andersen, A. H. (2008). Hairpin structures formed by alpha satellite DNA of human centromeres are cleaved by human topoisomerase Ila. Nucleic acids research, 36(19), 6165-6174.
  • Ju, B. G., Lunyak, V. V., Perissi, V., Garcia-Bassets, I., Rose, D. W., Glass, C. K., & Rosenfeld, M. G. (2006). A topoisomerase IIR-mediated dsDNA break required for regulated transcription. Science, 312(5781), 1798-1802.
  • Kadoch, C., Hargreaves, D. C., Hodges, C., Elias, L., Ho, L., Ranish, J., & Crabtree, G. R. (2013). Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nature genetics, 45(6), 592-601.
  • Kadoch, C., Williams, R. T., Calarco, J. P., Miller, E. L., Weber, C. M., Braun, S. M..... & Crabtree, G. R. (2017). Dynamics of BAF-Polycomb complex opposition on heterochromatin in normal and oncogenic states. Nature genetics, 49(2), 213-222.
  • Katyal, S., El-Khamisy, S. F., Russell, H. R., Li, Y., Ju, L., Caldecott, K. W., & McKinnon, P. J. (2007). TDP1 facilitates chromosomal single-strand break repair in neurons and is neuroprotective in vivo. The EMBO journal, 26(22), 4720-4731.
  • Katyal, S., Lee, Y., Nitiss, K. C., Downing, S. M., Li, Y., Shimada, M..... & McKinnon, P. J. (2014). Aberrant topoisomerase-1 DNA lesions are pathogenic in neurodegenerative genome instability syndromes. Nature neuroscience, 17(6), 813-821.
  • Khobta, A., Ferri, F., Lotito, L., Montecucco, A., Rossi, R., & Capranico, G. (2006). Early effects of topoisomerase I inhibition on RNA polymerase II along transcribed genes in human cells. Journal of molecular biology, 357(1), 127-138.
  • Kim, N., Huang, S. Y. N., Williams, J. S., Li, Y. C., Clark, A. B., Cho, J. E.....& Jinks-Robertson, S. (2011). Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. Science, 332(6037), 15611564.
  • King, I. F., Yandava, C. N., Mabb, A. M., Hsiao, J. S., Huang, H. S., Pearson, B. L., ... & Zylka, M. J. (20i3). Topoisomerases facilitate transcription of long genes linked to autism. Nature, 50Ï(7465), 58-62.
  • Kingma, P. S., Greider, C. A., S Osheroff, N. (i997). Spontaneous DNA lesions poison human topoisomerase IIa and stimulate cleavage proximal to leukemic iiq23 chromosomal breakpoints. Biochemistry, 36(20), 5934-5939.
  • Kosec, G., Alvarez, V. E., Agüero, F., Sánchez, D., Dolinar, M., Turk, B..... S Cazzulo, J. J. (2006). Metacaspases of Trypanosoma cruzi: possible candidates for programmed cell death mediators. Molecular and biochemical parasitology, Ï45(i), i8-28.
  • Kwan, K. Y., S Wang, J. C. (200i). Mice lacking DNA topoisomerase IIIß develop to maturity but show a reduced mean lifespan. Proceedings of the National Academy of Sciences, 98(i0), 57i7-572i.
  • Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, K., Dewar, K., and Doyle M. (200i). Initial sequencing and analysis of the human genome. Nature, 409, 860-92i.
  • Lee, S. K., S Wang, W. (20i9). Roles of topoisomerases in heterochromatin, aging, and diseases. Genes, Ï0(ii), 884.
  • Lehman, C. E., Dillon, L. W., Nikiforov, Y. E., S Wang, Y. H. (20i7). DNA fragile site breakage as a measure of chemical exposure and predictor of individual susceptibility to form oncogenic rearrangements. Carcinogenesis, 38(3), 293-30i.
  • Leone, G., Teofili, L., Voso, M. T., S Lubbert, M. (2002). DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. haematologica, 87(i2), i324-i34i.
  • Lesher, D. T. T., Pommier, Y., Stewart, L., S Redinbo, M. R. (2002). 8-Oxoguanine rearranges the active site of human topoisomerase I. Proceedings of the National Academy of Sciences, 99(i9), i2i02-i2i07.
  • Li, M., S Liu, Y. (20i6). Topoisomerase I in human disease pathogenesis and treatments. Genomics, Proteomics and Bioinformatics, Ï4(3), i66-i7i.
  • Lindsley, J. E., S Wang, J. C. (i99i). Proteolysis patterns of epitopically labeled yeast DNA topoisomerase II suggest an allosteric transition in the enzyme induced by ATP binding. Proceedings of the National Academy of Sciences, 88(23), 10485-10489.
  • Liu, L. F. (1989). DNA topoisomerase poisons as antitumor drugs. Annual review of biochemistry, 58(1), 351-375.
  • Liu, L. F., & Wang, J. C. (1983). DNA topoisomerases-enzymes that catalyse the breaking and rejoining of DNA. Critical Reviews in Biochemistry, 15(1), 124.
  • Liu, X., Gallay, C., Kjos, M., Domenech, A., Slager, J., van Kessel, S. P..... & Veening, J. W. (2017). High-throughput CRISPRi phenotyping identifies new essential genes in Streptococcus pneumoniae. Molecular systems biology, 13(5), 931.
  • Loike, J. D. (1982). VP16-213 and podophyllotoxin: a study on the relationship between chemical structure and biological activity. Cancer Chemotherapy and Pharmacology, 7, 103-111.
  • Long, B. H., & Stringfellow, D. A. (1988). Inhibitors of topoisomerase II: structure-activity relationships and mechanism of action of podophyllin congeners. Advances in enzyme regulation, 27, 211-214.
  • Mahler, M., Silverman, E. D., Schulte-Pelkum, J., & Fritzler, M. J. (2010). Anti-Scl-70 (topo-I) antibodies in SLE: myth or reality?. Autoimmunity reviews, 9(11), 756-760.
  • Manzo, S. G., Hartono, S. R., Sanz, L. A., Marinello, J., De Biasi, S., Cossarizza, A..... & Chedin, F. (2018). DNA Topoisomerase I differentially modulates R-loops across the human genome. Genome biology, 19, 1-18.
  • Mao, Y., Desai, S. D., Ting, C. Y., Hwang, J., & Liu, L. F. (2001). 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes. Journal of Biological Chemistry, 276(44), 40652-40658.
  • Marchand, C., & Pommier, Y. (2011). Topoisomerases inhibitors: a paradigm for interfacial inhibition. In DNA Topoisomerases and Cancer (pp. 175184). New York, NY: Springer New York.
  • McClendon, A. K., & Osheroff, N. (2007). DNA topoisomerase II, genotoxicity, and cancer. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 623(1-2), 83-97.
  • Meyer, C., Burmeister, T., Groger, D., Tsaur, G., Fechina, L., Renneville, A..... & Marschalek, R. (2018). The MLL recombinome of acute leukemias in 2017. Leukemia, 32(2), 273-284.
  • Miller, E. L., Hargreaves, D. C., Kadoch, C., Chang, C. Y., Calarco, J. P., Hodges, C.....& Crabtree, G. R. (2017). TOP2 synergizes with BAF chromatin remodeling for both resolution and formation of facultative heterochromatin. Nature structural & molecular biology, 24(4), 344-352.
  • Mills, W. E., Spence, J. M., Fukagawa, T., & Farr, C. J. (2018). Site-Specific cleavage by topoisomerase 2: a mark of the core centromere. International Journal of Molecular Sciences, 19(2), 534.
  • Morton, L. M., Dores, G. M., Tucker, M. A., Kim, C. J., Onel, K., Gilbert, E. S..... & Curtis, R. E. (2013). Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood, The Journal of the American Society of Hematology, 121(15), 2996-3004.
  • National Toxicology Program. (2011). NTP 12th report on carcinogens. Report on carcinogens: carcinogen profiles, 12, iii-499.
  • Nikiforov, Y. E., Rowland, J. M., Bove, K. E., Monforte-Munoz, H., & Fagin, J. A. (1997). Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Research, 57(9), 1690-1694.
  • Nitiss, J. L. (1998). Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression, 1400(1-3), 63-81.
  • Nitiss, J. L., & Beck, W. T. (1996). Antitopoisomerase drug action and resistance. European Journal of Cancer, 32(6), 958-966.
  • Osheroff, N. (1986). Eukaryotic topoisomerase II. Characterization of enzyme turnover. Journal of Biological Chemistry, 261(21), 9944-9950.
  • Osheroff, N., Shelton, E. R., & Brutlag, D. L. (1983). DNA topoisomerase II from Drosophila melanogaster. Relaxation of supercoiled DNA. Journal of Biological Chemistry, 258(15), 9536-9543.
  • Pedersen-Bjergaard, J., & Philip, P. (1991). Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II.
  • Pham, T. D., Ziora, Z. M., & Blaskovich, M. A. (2019). Quinolone antibiotics. Medchemcomm, 10(10), 1719-1739.
  • Pommier, Y., & Cherfils, J. (2005). Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. Trends in pharmacological sciences, 26(3), 138-145.
  • Pommier, Y., & Marchand, C. (2005). Interfacial inhibitors of protein-nucleic acid interactions. Current Medicinal Chemistry-Anti-Cancer Agents, 5(4), 421-429.
  • Pommier, Y., & Marchand, C. (2012). Interfacial inhibitors: targeting macromolecular complexes. Nature reviews Drug discovery, 11(1), 25-36.
  • Pommier, Y., Barcelo, J. M., Rao, V. A., Sordet, O., Jobson, A. G., Thibaut, L., ... & Redon, C. (2006). Repair of topoisomerase I-mediated DNA damage. Progress in nucleic acid research and molecular biology, 81, 179-229.
  • Pommier, Y., Capranico, G., Orr, A., & Kohn, K. W. (1991). Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugs. Journal of molecular biology, 222(4), 909924.
  • Pommier, Y., Capranico, G., Orr, A., & Kohn, K. W. (1991a). Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. Nucleic acids research, 19(21), 5973-5980.
  • Pommier, Y., Kiselev, E., & Marchand, C. (2015). Interfacial inhibitors. Bioorganic & medicinal chemistry letters, 25(18), 3961-3965.
  • Pommier, Y., Leo, E., Zhang, H., & Marchand, C. (2010). DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chemistry & biology, 17(5), 421-433.
  • Pommier, Y., Pourquier, P., Fan, Y. I., & Strumberg, D. (1998). Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression, 1400(1-3), 83106.
  • Pourquier, P., Pilon, A. A., Kohlhagen, G., Mazumder, A., Sharma, A., & Pommier, Y. (1997). Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps: importance of DNA end phosphorylation and camptothecin effects. Journal of Biological Chemistry, 272(42), 26441-26447.
  • Pourquier, P., Ueng, L. M., Fertala, J., Wang, D., Park, H. J., Essigmann, J. M.....& Pommier, Y. (1999). Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages: 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine. Journal of Biological Chemistry, 274(13), 8516-8523.
  • Pourquier, P., Ueng, L. M., Kohlhagen, G., Mazumder, A., Gupta, M., Kohn, K. W., & Pommier, Y. (1997a). Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. Journal of Biological Chemistry, 272(12), 7792-7796.
  • Prasanth, K. R., Hirano, M., Fagg, W. S., McAnarney, E. T., Shan, C., Xie, X..... & Garcia-Blanco, M. A. (2020). Topoisomerase III-ß is required for efficient replication of positive-sense RNA viruses. Antiviral research, 182, 104874.
  • Ravishankar, S., Ambady, A., Awasthy, D., Mudugal, N. V., Menasinakai, S., Jatheendranath, S..... & Sharma, U. K. (2015). Genetic and chemical validation identifies Mycobacterium tuberculosis topoisomerase I as an attractive anti-tubercular target. Tuberculosis, 95(5), 589-598.
  • Sabourin, M., & Osheroff, N. (2000). Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions. Nucleic acids research, 28(9), 1947-1954.
  • Sander, M., & Hsieh, T. S. (1983). Double strand DNA cleavage by type II DNA topoisomerase from Drosophila melanogaster. Journal of Biological Chemistry, 258(13), 8421-8428.
  • SanMiguel, P., Tikhonov, A., Jin, Y. K., Motchoulskaia, N., Zakharov, D., Melake-Berhan, A..... & Bennetzen, J. L. (1996). Nested retrotransposons in the intergenic regions of the maize genome. Science, 274(5288), 765-768.
  • Seddek, A., Annamalai, T., & Tse-Dinh, Y. C. (2021). Type IA topoisomerases as targets for infectious disease treatments. Microorganisms, 9(1), 86.
  • Sen, N., Das, B. B., Ganguly, A., Mukherjee, T., Bandyopadhyay, S., & Majumder, H. K. (2004). Camptothecin-induced imbalance in intracellular cation homeostasis regulates programmed cell death in unicellular hemoflagellate Leishmania donovani. Journal of Biological Chemistry, 279(50), 52366-52375.
  • Sen, N., Das, B.B., Ganguly, A., Mukherjee, T., Tripathi, G., and Bandopadhyay, S., et al. (2004a) Camptothecin induced mitochondrial dysfunction and programmed cell death in unicellular hemoflagellate Leishmania donovani. Cell Death Diff, 11, 924-936.
  • Shuman, S. (1989). Vaccinia DNA topoisomerase I promotes illegitimate recombination in Escherichia coli. Proceedings of the National Academy of Sciences, 86(10), 3489-3493.
  • Solary, E., Bertrand, R., & Pommier, Y. (1994). Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells. Leukemia & lymphoma, 15(1-2), 21-32.
  • Staker, B. L., Hjerrild, K., Feese, M. D., Behnke, C. A., Burgin Jr, A. B., & Stewart, L. (2002). The mechanism of topoisomerase I poisoning by a camptothecin analog. Proceedings of the National Academy of Sciences, 99(24), 15387-15392.
  • Stewart, L., Redinbo, M. R., Qiu, X., Hol, W. G., & Champoux, J. J. (1998). A model for the mechanism of human topoisomerase I. Science, 279(5356), 1534-1541.
  • Stoll, G., Pietiläinen, O. P., Linder, B., Suvisaari, J., Brosi, C., Hennah, W., ... & Palotie, A. (2013). Deletion of TOP3ß, a component of FMRP-containing mRNPs, contributes to neurodevelopmental disorders. Nature neuroscience, 16(9), 1228-1237.
  • Strick, R., Strissel, P. L., Borgers, S., Smith, S. L., & Rowley, J. D. (2000). Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proceedings of the National Academy of Sciences, 97(9), 4790-4795.
  • Swan, R. L., Cowell, I. G., & Austin, C. A. (2022). Mechanisms to repair stalled topoisomerase II-DNA covalent complexes. Molecular Pharmacology, 101(1), 24-32.
  • Swerdlow, A. J., Douglas, A. J., Hudson, G. V., Hudson, B. V., Bennett, M. H., & MacLennan, K. A. (1992). Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. British Medical Journal, 304(6835), 1137-1143.
  • Takashima, H., Boerkoel, C. F., John, J., Saifi, G. M., Salih, M. A., Armstrong, D..... & Lupski, J. R. (2002). Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nature genetics, 32(2), 267-272.
  • Tanizawa, A., Kohn, K. W., Kohlhagen, G., Leteurtre, F., & Pommier, Y. (1995). Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry, 34(21), 7200-7206.
  • Tenreiro, S., Eckermann, K., & Outeiro, T. F. (2014). Protein phosphorylation in neurodegeneration: friend or foe?. Frontiers in molecular neuroscience, 7, 42.
  • Terekhova, K., Gunn, K. H., Marko, J. F., & Mondragon, A. (2012). Bacterial topoisomerase I and topoisomerase III relax supercoiled DNA via distinct pathways. Nucleic acids research, 40(20), 10432-10440.
  • Terekhova, K., Marko, J. F., & Mondragon, A. (2014). Single-molecule analysis uncovers the difference between the kinetics of DNA decatenation by bacterial topoisomerases I and III. Nucleic acids research, 42(18), 11657-11667.
  • Tewey, K. M., Chen, G. L., Nelson, E. M., & Liu, L. F. (1984). Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. Journal of Biological Chemistry, 259(14), 9182-9187.
  • Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. (1984a). Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science, 226(4673), 466-468.
  • Thys, R. G., Lehman, C. E., Pierce, L. C., & Wang, Y. H. (2015). Environmental and chemotherapeutic agents induce breakage at genes involved in leukemia-causing gene rearrangements in human hematopoietic stem/progenitor cells. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 779, 86-95.
  • Tsuchiya, H., Tomita, K., Ohno, M., Inaoki, M., & Kawashima, A. (1991). Werner's syndrome combined with quintuplicate malignant tumors: a case report and review of literature data. Japanese journal of clinical oncology, 21(2), 135-142.
  • Tuduri, S., Crabbe, L., Conti, C., Tourriere, H., Holtgreve-Grez, H., Jauch, A..... & Pasero, P. (2010). Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nature Cell Biology, 12(11), 1122.
  • Velez-Cruz, R., & Osheroff, N. (2004). DNA topoisomerases: type II. in: Encyclopedia of Biological Chemistry." Elsevier Inc, p: 806-811.
  • Venkitaraman, R., Affolter, A., Ahmed, M., Thomas, V., Pritchard-Jones, K., Sharma, A. K.....& Nutting, C. M. (2008). Childhood papillary thyroid cancer as second malignancy after successful treatment of rhabdomyosarcoma. Acta Oncologica, 47(3), 469472.
  • Verneris, M., McDougall, I. R., Becton, D., & Link, M. P. (2001). Thyroid carcinoma after successful treatment of osteosarcoma: a report of three patients. Journal of pediatric hematology/oncology, 23(5), 312-315.
  • Villeponteau, B. (1997). The heterochromatin loss model of aging. Experimental gerontology, 32(4-5), 383394.
  • Walton, C., Interthal, H., Hirano, R., Salih, M. A., Takashima, H., & Boerkoel, C. F. (2010). Spinocerebellar ataxia with axonal neuropathy. Diseases of DNA Repair, 75-83.
  • Wang, J. C. (1996). DNA topoisomerases. Annu Rev Biochem, 65, 635-692.
  • Wang, J. C. (2002). Cellular roles of DNA topoisomerases: a molecular perspective. Nature reviews Molecular cell biology, 3(6), 430-440.
  • Waterston, R. H., Lindblad-Toh, K., Birney, E., Rogers, J., Abril, J. F., Agarwal, P..... & Bult, C. (2002). Initial sequencing and comparative analysis of the mouse genome: Mouse Genome Sequencing Consortium.
  • Watson, J. D., Baker, T. A., Bell, S. P., Gann, A., Levine, M., Losick R. (2013). Molecular biology of the gene. 7th edition., Pearson Education, 880 p.
  • Woessner, R. D., Mattern, M. R., Mirabelli, C. K., Johnson, R. K., & Drake, F. H. (1991). Proliferation-and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ, 2(4), 209-214.
  • Worland, S. T., & Wang, J. C. (1989). Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae. Journal of Biological Chemistry, 264(8), 4412-4416.
  • Wu, J., & Liu, L. F. (1997). Processing of topoisomerase I cleavable complexes into DNA damage by transcription. Nucleic acids research, 25(21), 41814186.
  • Wu, L., & Hickson, I. D. (2003). The Bloom's syndrome helicase suppresses crossing over during homologous recombination. Nature, 426(6968), 870-874.
  • Yan, R., Hu, S., Ma, N., Song, P., Liang, Q., Zhang, H.....& Chen, L. (2019). Regulatory effect of DNA topoisomerase I on T3SS activity, antibiotic susceptibility and quorum-sensing-independent pyocyanin synthesis in Pseudomonas aeruginosa. International journal of molecular sciences, 20(5), 1116.
  • Yen, B. C., Kahn, H., Schiller, A. L., Klein, M. J., Phelps, R. G., & Lebwohl, M. G. (1993). Multiple hamartoma syndrome with osteosarcoma. Archives of pathology & laboratory medicine, 117(12), 1252-1254.
  • Yunis, J. J., Soreng, A. L., & Bowe, A. E. (1987). Fragile sites are targets of diverse mutagens and carcinogens. Oncogene, 1(1), 59-69.
  • Zechiedrich, E. L., Christiansen, K., Andersen, A. H., Westergaard, O., & Osheroff, N. (1989). Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate. Biochemistry, 28(15), 62296236.
  • Zhang, T., Wallis, M., Petrovic, V., Challis, J., Kalitsis, P., & Hudson, D. F. (2019). Loss of TOP3B leads to increased R-loop formation and genome instability. Open Biology, 9(12), 190222.
  • Zuma, A. A., Cavalcanti, D. P., Maia, M. C., de Souza, W., & Motta, M. C. M. (2011). Effect of topoisomerase inhibitors and DNA-binding drugs on the cell proliferation and ultrastructure of Trypanosoma cruzi. International journal of antimicrobial agents, 37(5), 449-456.
  • Zylka, M. J., Simon, J. M., & Philpot, B. D. (2015). Gene length matters in neurons. Neuron, 86(2), 353-355.
Еще
Статья обзорная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp